The Pluses and Minuses of Innovation
Applied Clinical Trials
Survey delves deep into what constitutes true game-changing innovation in clinical development.
There is hype. And there is innovation. There are expectations and reality. While the chart below is from our latest survey conducted with SCORR Marketing on innovation, this question itself doesn’t use the “i” word. Something that has the “potential to change the future of clinical trials” should be considered an innovation, but of the five choices we gave, which is a true innovation? And does it matter if it indeed changes the future?
The survey delved much deeper into what respondents think about innovation, what types of innovation is or is not being implemented, and how innovation is viewed by stakeholders. These results can be download for free here.
Other items of note from the survey include the majority of respondents feel that CROs are most accepting of innovative processes, while clinical sites are not; an equal number of companies have or don’t have an innovations department or infrastructure (43.4%); and the most often cited reason for hindering adoption of technological advances is cost.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
